Antithrombotic Drugs

Drug Safety Update

 December 2014: Prasugrel (Efient▼): rare but serious hypersensitivity reactions

  January 2014: Prasugrel increased risk of bleeding advice on loading dose

NICE Guidance (also see drug-specific links below)

 TA52: Guidance on the use of drugs for early thrombolysis in the treatment of acute MI, Oct 2002

 TA47: Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of ACS, updated March 2010

  NG128: Stroke and transient ischaemic attack in over 16s: diagnosis and initial management

Aspirin and clopidogrel are also used in the management of patients with acute coronary syndromes. See NICE guidance and section Antiplatelet drugs.

Tenecteplase is approved as an option for the treatment of acute, ischaemic stroke falling within the window for thrombolytic treatment. It is hospital only for specialist prescribing.

Cangrelor is for use by specialists at EKHUFT.

Alteplase is also approved for intrapleural use in hospital by a respiratory consultant for the management of pleural infection in adults (unlicensed indication and route). It is to be requested from pharmacy on an individual patient basis only for this indication.

For use by specialists at EKHUFT only.

Cangrelor should be considered as a second line therapy. Its role in treatment is limited to those patients who have not received an oral P2Y12 inhibitor (e.g. clopidogrel, prasugrel, ticagrelor) prior to a PCI procedure.

Cangrelor co-administered with aspirin, should be considered as a preferred treatment option for whom oral therapy with P2Y12 inhibitors is not feasible or desirable to replace use of crushed P2Y12 inhibitors given via an NG tube, or to replace use of injectable glycoprotein IIb/IIIa inhibitors (GPI) in this patient group.

Pack
10 vial
  • On Formulary Preferred
  • On Formulary Second Line
  • On Formulary Third Line
  • Specialist Initiation
  • Secondary Care Only
  • Not Approved for Formulary